Newsroom

Industry News

2 Mar

Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March

NEWTOWN, Pa., March 02, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Company management will present an overview at: Maxim Inaugural Healthcare Investor and Partnering Conference in China 29th...

Read more

1 Mar

Check-Cap to Present at the 29th Annual ROTH Conference on March 14, 2017

ISFIYA, Israel, March 1, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced that Bill Densel, Chief Executive Officer, will present at the 29th...

Read more

1 Mar

Drone Aviation Delivers Enhanced WASP Tactical Aerostat to U.S. Department Supporting Multiple Communications and Optical Payloads

JACKSONVILLE, FL–(Marketwired – March 01, 2017) – Drone Aviation Holding Corp. (DRNE) (“Drone Aviation” or the “Company”), a manufacturer of tethered drones and lighter-than-air aerostats, today announced that it has successfully completed the integration of Government-furnished ISR equipment supporting the simultaneous use of communications and optical payload packages onto...

Read more

28 Feb

Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company received a notice of allowance from the United States Patent and Trademark Office...

Read more

27 Feb

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

SAN DIEGO, Feb. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic...

Read more

Page 5 of 222« First...34567...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address